Serum magnesium levels in neonatal jaundice: Is there any correlation between hypermagnesemia and moderate to severe hyperbilirubinemia in term newborns?

Background: Neonatal jaundice is a common major problem; on the other hand, it is suggested that there is a correlation between plasma magnesium concentrations and hyperbilirubinemia during the neonatal period. Objectives: The study aims to validate a previously reported risk index for predicting the magnesium level of plasma for moderate to severe hyperbilirubinemia in infant neonates. Methods: A cross-sectional correlation study was performed on 93 term newborns with indirect hyperbilirubinemia admitted in neonatology unit of a children hospital and plasma magnesium level of moderate to severe Neonatal hyperbilirubinemia were determined, and statistical analysis was performed. Results: Authors did not find any statistically meaningful positive or negative correlation between plasma Mg level and bilirubin in patients studied; however, comparison of Mg level in two groups of severe and moderate hyperbilirubinemia showed decreased dispersion of medium Mg level in the severe group. Conclusions: Serum magnesium concentration is not useful in anticipation of which newborn infant will develop hyperbilirubinemia. Copyright © 2020, Journal of Comprehensive Pediatrics

The effects of helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia

Background Helicobactor pylori (H. pylori) have the potential role in the pathogenesis of various extra-gastric disorders such as metabolic disorders. But, it is now questioned about whether H. pylori eradication reduces or induces the risk for metabolic disorders especially in patients with dyspepsia. Hence, the present study aimed to assess the effects of H. pylori eradication on criteria of metabolic syndrome. Methods H. pylori infected patients with dyspepsia were included. The patients were treated with omeprazole (20 mg, q12 h), amoxicillin (1 g, q12 h), and clarithromycin (500 mg, q12 h) for two weeks, then H. pylori eradication was evaluated by C14 Breathing test (UBT) 6 weeks after the end of the treatment. Demographic data, clinical manifestation and metabolic parameters were recorded before and three months after completing treatment regimen. The data was analyzed by SPSS version 16.0. Results Of 110 patients were initially enrolled, 91 patients completed the study. Overall eradication rate was 61.5. Significant differences in the serum level of total cholesterol(180.7 ± 34 vs. 172.1 ± 28, p = 0.001), LDL(107.0 ± 25 vs. 100.8 ± 20, p < 0.001), HDL(46.2 ± 8.7 vs. 48.9 ± 8.6, p < 0.001), fasting blood sugar (93.7 ± 12 vs. 90.9 ± 10, p = 0.001), hemoglobin A1c(5.37 ± 0.52 vs 5.25 ± 0.53, p = 0.006), and as well as for waist circumference(92.2 ± 14 vs. 91.4 ± 13.9, p = 0.03) was found after treatment. Data for body weight, systolic and diastolic blood pressure and triglyceride level remained without any significant changes. Conclusion H. pylori eradication could relatively reduce the risk of metabolic syndrome criteria such as fasting blood sugar, hemoglobin A1c, lipid profile and waist circumference. © 2017 Diabetes Indi

The effects of helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia

Background Helicobactor pylori (H. pylori) have the potential role in the pathogenesis of various extra-gastric disorders such as metabolic disorders. But, it is now questioned about whether H. pylori eradication reduces or induces the risk for metabolic disorders especially in patients with dyspepsia. Hence, the present study aimed to assess the effects of H. pylori eradication on criteria of metabolic syndrome. Methods H. pylori infected patients with dyspepsia were included. The patients were treated with omeprazole (20 mg, q12 h), amoxicillin (1 g, q12 h), and clarithromycin (500 mg, q12 h) for two weeks, then H. pylori eradication was evaluated by C14 Breathing test (UBT) 6 weeks after the end of the treatment. Demographic data, clinical manifestation and metabolic parameters were recorded before and three months after completing treatment regimen. The data was analyzed by SPSS version 16.0. Results Of 110 patients were initially enrolled, 91 patients completed the study. Overall eradication rate was 61.5. Significant differences in the serum level of total cholesterol(180.7 ± 34 vs. 172.1 ± 28, p = 0.001), LDL(107.0 ± 25 vs. 100.8 ± 20, p < 0.001), HDL(46.2 ± 8.7 vs. 48.9 ± 8.6, p < 0.001), fasting blood sugar (93.7 ± 12 vs. 90.9 ± 10, p = 0.001), hemoglobin A1c(5.37 ± 0.52 vs 5.25 ± 0.53, p = 0.006), and as well as for waist circumference(92.2 ± 14 vs. 91.4 ± 13.9, p = 0.03) was found after treatment. Data for body weight, systolic and diastolic blood pressure and triglyceride level remained without any significant changes. Conclusion H. pylori eradication could relatively reduce the risk of metabolic syndrome criteria such as fasting blood sugar, hemoglobin A1c, lipid profile and waist circumference. © 2017 Diabetes Indi